TR201815811T4 - İduronat-2-sülfataz'ın saflaştırılması. - Google Patents

İduronat-2-sülfataz'ın saflaştırılması. Download PDF

Info

Publication number
TR201815811T4
TR201815811T4 TR2018/15811T TR201815811T TR201815811T4 TR 201815811 T4 TR201815811 T4 TR 201815811T4 TR 2018/15811 T TR2018/15811 T TR 2018/15811T TR 201815811 T TR201815811 T TR 201815811T TR 201815811 T4 TR201815811 T4 TR 201815811T4
Authority
TR
Turkey
Prior art keywords
protein
recombinant
izs
purified recombinant
composition according
Prior art date
Application number
TR2018/15811T
Other languages
English (en)
Turkish (tr)
Inventor
Nichols Dave
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49778401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201815811(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of TR201815811T4 publication Critical patent/TR201815811T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
TR2018/15811T 2012-06-29 2013-06-28 İduronat-2-sülfataz'ın saflaştırılması. TR201815811T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261666733P 2012-06-29 2012-06-29

Publications (1)

Publication Number Publication Date
TR201815811T4 true TR201815811T4 (tr) 2018-11-21

Family

ID=49778401

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/15811T TR201815811T4 (tr) 2012-06-29 2013-06-28 İduronat-2-sülfataz'ın saflaştırılması.

Country Status (39)

Country Link
US (7) US9051556B2 (cg-RX-API-DMAC7.html)
EP (2) EP3441398A1 (cg-RX-API-DMAC7.html)
JP (4) JP6171007B2 (cg-RX-API-DMAC7.html)
KR (5) KR101380740B1 (cg-RX-API-DMAC7.html)
CN (3) CN107596358A (cg-RX-API-DMAC7.html)
AR (1) AR091647A1 (cg-RX-API-DMAC7.html)
AU (3) AU2013282395C1 (cg-RX-API-DMAC7.html)
BR (1) BR112014032567B1 (cg-RX-API-DMAC7.html)
CA (2) CA2877517C (cg-RX-API-DMAC7.html)
CL (1) CL2014003567A1 (cg-RX-API-DMAC7.html)
CO (1) CO7240396A2 (cg-RX-API-DMAC7.html)
CR (1) CR20140588A (cg-RX-API-DMAC7.html)
CY (1) CY1121519T1 (cg-RX-API-DMAC7.html)
DK (1) DK2867245T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2014000294A (cg-RX-API-DMAC7.html)
EA (2) EA202090044A1 (cg-RX-API-DMAC7.html)
ES (1) ES2689468T3 (cg-RX-API-DMAC7.html)
GT (1) GT201400303A (cg-RX-API-DMAC7.html)
HK (3) HK1209431A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20181897T1 (cg-RX-API-DMAC7.html)
HU (1) HUE040769T2 (cg-RX-API-DMAC7.html)
IL (4) IL236315A (cg-RX-API-DMAC7.html)
LT (1) LT2867245T (cg-RX-API-DMAC7.html)
MX (3) MX366906B (cg-RX-API-DMAC7.html)
MY (3) MY180287A (cg-RX-API-DMAC7.html)
NZ (3) NZ733366A (cg-RX-API-DMAC7.html)
PE (1) PE20150720A1 (cg-RX-API-DMAC7.html)
PH (3) PH12014502871A1 (cg-RX-API-DMAC7.html)
PL (1) PL2867245T3 (cg-RX-API-DMAC7.html)
PT (1) PT2867245T (cg-RX-API-DMAC7.html)
RS (1) RS58005B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201408761VA (cg-RX-API-DMAC7.html)
SI (1) SI2867245T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800612T1 (cg-RX-API-DMAC7.html)
TR (1) TR201815811T4 (cg-RX-API-DMAC7.html)
TW (2) TWI553120B (cg-RX-API-DMAC7.html)
UA (2) UA129561C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014005014A2 (cg-RX-API-DMAC7.html)
ZA (2) ZA201409397B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009018122A2 (en) 2007-07-27 2009-02-05 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the cns
EP2485761B1 (en) 2009-10-09 2019-02-27 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
CN109641971B (zh) 2016-08-25 2023-04-04 Jcr制药股份有限公司 抗体融合蛋白的制造方法
CN106282231B (zh) * 2016-09-06 2020-01-03 陕西慧康生物科技有限责任公司 粘多糖贮积症ii型动物模型的构建方法及应用
CN106428420B (zh) * 2016-10-17 2018-08-21 上海江南长兴造船有限责任公司 一种用于超大型集装箱船止裂钢舱口围的安装的方法
US20200277584A1 (en) 2017-10-02 2020-09-03 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
EP3898689A1 (en) * 2018-12-20 2021-10-27 Armagen, Inc. Purification of iduronate-2-sulfatase immunoglobulin fusion protein
US20220098279A1 (en) * 2019-01-30 2022-03-31 Amgen Inc. Aflibercept attributes and methods of characterizing and modifying thereof
AU2020398898A1 (en) 2019-12-09 2022-07-21 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
JP2023546682A (ja) * 2020-10-23 2023-11-07 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼの製造中に総シアル酸含量（ｔｓａｃ）を制御する方法
CN117042791A (zh) 2021-02-12 2023-11-10 阿雷克森制药公司 碱性磷酸酶多肽及其使用方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
CA2185324A1 (en) 1994-03-16 1995-09-21 Steven D. Rosen Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
DE19527054A1 (de) 1995-07-26 1997-01-30 Behringwerke Ag Verfahren zur Charakterisierung der Glycosylierung von Glycoproteinen sowie zur in-vitro Bestimmung der Bioverfügbarkeit von Glycoproteinen
EP2221361A3 (en) 1996-08-30 2011-02-09 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
WO2001018022A1 (en) 1999-09-03 2001-03-15 Human Genome Sciences, Inc. 52 human secreted proteins
WO2000050443A2 (en) 1999-02-26 2000-08-31 Millennium Pharmaceutcals, Inc. Secreted proteins and uses thereof
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
ATE348173T1 (de) 1999-04-26 2007-01-15 Genentech Inc Zellenzuchtverfahren für glycoproteine
JP2002017376A (ja) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
WO2001060991A2 (en) 2000-02-17 2001-08-23 Incyte Genomics, Inc. Human kinases
CA2400638A1 (en) 2000-03-17 2001-09-27 Human Genome Sciences, Inc. 7 human ovarian and ovarian cancer associated proteins
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
WO2002098455A2 (en) 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human arylsulfatase a
WO2003102132A2 (en) 2002-04-26 2003-12-11 Genetech, Inc. Non-affinity purification of proteins
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
PL377731A1 (pl) 2002-12-23 2006-02-06 Bristol-Myers Squibb Company Sposoby hodowli komórek ssaczych do wytwarzania białka
JP4606712B2 (ja) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー ２−ｏスルファターゼ組成物および関連の方法
EP2325301B1 (en) 2003-02-11 2015-09-02 Shire Human Genetic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and others using a formylglycine generating enzyme (FGE)
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
WO2005073367A1 (en) 2004-01-30 2005-08-11 Zymenex A/S Production and purification of recombinant arylsulfatase a
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
SI2267024T1 (sl) 2005-06-03 2012-09-28 Ares Trading Sa Proizvodnja rekombinantnega IL-18 vezavnega proteina
CN101437839A (zh) 2006-03-20 2009-05-20 米德列斯公司 蛋白质纯化
JP4458377B2 (ja) 2007-06-29 2010-04-28 キヤノン株式会社 プロセスカートリッジ及び電子写真画像形成装置
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
US8128925B2 (en) * 2008-01-18 2012-03-06 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
EP2485761B1 (en) 2009-10-09 2019-02-27 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
WO2011108451A1 (ja) * 2010-03-01 2011-09-09 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
JP6063380B2 (ja) * 2010-06-25 2017-01-18 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド サンフィリポ症候群ｂ型の処置
SMT201900594T1 (it) 2010-06-25 2019-11-13 Shire Human Genetic Therapies Metodi e composizioni per il rilascio nell’snc di iduronato-2-solfatasi
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
CN103153337A (zh) * 2010-09-28 2013-06-12 共立制药股份有限公司 黏膜佐剂组合物
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
KR20130114704A (ko) 2011-01-31 2013-10-17 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. 동적으로 튜닝 가능한 산란각을 갖는 산광기
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) * 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
KR20190062745A (ko) 2017-11-29 2019-06-07 주식회사 위니플 쇼핑몰 모바일앱 빌더

Also Published As

Publication number Publication date
US20190359958A1 (en) 2019-11-28
US20210317426A1 (en) 2021-10-14
CO7240396A2 (es) 2015-04-17
PH12020500027A1 (en) 2021-03-15
IL261264A (en) 2018-10-31
AU2016200469B2 (en) 2017-10-12
PH12014502871B1 (en) 2015-02-23
UA129561C2 (uk) 2025-06-04
TWI553120B (zh) 2016-10-11
IL236315A0 (en) 2015-02-26
JP2015523072A (ja) 2015-08-13
KR20220002227A (ko) 2022-01-06
MX393364B (es) 2025-03-19
IL261264B (en) 2021-10-31
ZA201409397B (en) 2019-10-30
CN107596358A (zh) 2018-01-19
TW201703794A (zh) 2017-02-01
AU2013282395B2 (en) 2015-12-03
LT2867245T (lt) 2018-11-12
US12359178B2 (en) 2025-07-15
MX2019008914A (es) 2019-09-26
KR101380740B1 (ko) 2014-04-11
CA2877517A1 (en) 2014-01-03
AU2018200230A1 (en) 2018-02-01
HK1249026A1 (zh) 2018-10-26
SMT201800612T1 (it) 2019-01-11
US11530393B2 (en) 2022-12-20
JP6171007B2 (ja) 2017-07-26
MX2015000190A (es) 2015-04-08
JP7594365B2 (ja) 2024-12-04
HK1249027A1 (zh) 2018-10-26
CY1121519T1 (el) 2020-05-29
NZ743910A (en) 2019-12-20
US20240043817A1 (en) 2024-02-08
SG11201408761VA (en) 2015-01-29
RS58005B1 (sr) 2019-02-28
US9051556B2 (en) 2015-06-09
CA2877517C (en) 2018-07-31
BR112014032567A2 (pt) 2017-08-01
IL236315A (en) 2016-11-30
MY157087A (en) 2016-04-19
NZ733366A (en) 2019-12-20
ES2689468T3 (es) 2018-11-14
KR20190064542A (ko) 2019-06-10
AU2013282395C1 (en) 2016-03-24
PH12015502408A1 (en) 2018-03-26
PH12014502871A1 (en) 2015-02-23
KR20140004603A (ko) 2014-01-13
HK1209431A1 (en) 2016-04-01
PT2867245T (pt) 2018-11-26
HRP20181897T1 (hr) 2019-01-11
JP2018121645A (ja) 2018-08-09
UA121959C2 (uk) 2020-08-25
MX336715B (es) 2016-01-28
MY180287A (en) 2020-11-27
EP3441398A1 (en) 2019-02-13
EA202090044A1 (ru) 2020-07-31
CL2014003567A1 (es) 2015-04-24
IL287057A (en) 2021-12-01
HUE040769T2 (hu) 2019-03-28
PL2867245T3 (pl) 2019-02-28
SI2867245T1 (sl) 2018-12-31
TW201410868A (zh) 2014-03-16
AU2018200230B2 (en) 2020-01-02
US20140004096A1 (en) 2014-01-02
JP2016119911A (ja) 2016-07-07
CA3008945A1 (en) 2014-01-03
AU2016200469A1 (en) 2016-02-18
EA201492177A1 (ru) 2015-06-30
DK2867245T3 (en) 2018-11-26
CN107596357A (zh) 2018-01-19
US20150313972A1 (en) 2015-11-05
PE20150720A1 (es) 2015-05-16
PH12015502408B1 (en) 2020-02-14
BR112014032567B1 (pt) 2022-09-13
EP2867245A4 (en) 2016-03-09
MX366906B (es) 2019-07-30
KR20200143339A (ko) 2020-12-23
US20240401010A1 (en) 2024-12-05
US10344270B2 (en) 2019-07-09
KR20140002451A (ko) 2014-01-08
EA034549B1 (ru) 2020-02-19
SG10201703489VA (en) 2017-05-30
CN104583225A (zh) 2015-04-29
JP2020105209A (ja) 2020-07-09
EP2867245B1 (en) 2018-09-12
TWI587869B (zh) 2017-06-21
AU2013282395A1 (en) 2015-01-29
IL248727A0 (en) 2017-01-31
GT201400303A (es) 2017-08-31
CR20140588A (es) 2015-04-06
HK1209767A1 (en) 2016-04-08
AR091647A1 (es) 2015-02-18
EP2867245A2 (en) 2015-05-06
MY192068A (en) 2022-07-25
NZ703093A (en) 2017-08-25
JP6505629B2 (ja) 2019-04-24
DOP2014000294A (es) 2015-03-15
ZA201803289B (en) 2021-04-28
US20170073652A1 (en) 2017-03-16
US9492511B2 (en) 2016-11-15
WO2014005014A3 (en) 2014-02-27
WO2014005014A2 (en) 2014-01-03

Similar Documents

Publication Publication Date Title
TR201815811T4 (tr) İduronat-2-sülfataz'ın saflaştırılması.
HK1209767B (en) Purification of iduronate-2-sulfatase